TICKERNOMICS Sign up
Last Update: 2023-12-23 06:02:52
Turnstone Biologics Corp. ( TSBX )
2.48USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
TSBX
0.00%
SPY
30.72%
TSBX
0.00%
SPY
112.82%
TSBX
0.00%
SPY
201.04%
TSBX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
43.15
-23.50
0.05
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.82
0.53
0.38
-164.62
0.00
0.45
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-113.19
100.00
-76.02
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
-90.84
-56.60
0.00
Other Earnings and Cash Flow Stats:
Turnstone Biologics Corp. ( TSBX ) Net Income TTM ($MM) is -47.07
Turnstone Biologics Corp. ( TSBX ) Operating Income TTM ($MM) is -49.71
Turnstone Biologics Corp. ( TSBX ) Owners' Earnings Annual ($MM) is 0.00
Turnstone Biologics Corp. ( TSBX ) Current Price to Owners' Earnings ratio is 0.00
Turnstone Biologics Corp. ( TSBX ) EBITDA TTM ($MM) is -46.02
Turnstone Biologics Corp. ( TSBX ) EBITDA Margin is -76.02%
Capital Allocation:
Turnstone Biologics Corp. ( TSBX ) has paid 0.00 dividends per share and bought back 4.790837 million shares in the past 12 months
Turnstone Biologics Corp. ( TSBX ) has increased its debt by 3.679 million USD in the last 12 months
Capital Structure:
Turnstone Biologics Corp. ( TSBX ) Interest-bearing Debt ($MM) as of last quarter is 3
Turnstone Biologics Corp. ( TSBX ) Annual Working Capital Investments ($MM) are -1
Turnstone Biologics Corp. ( TSBX ) Book Value ($MM) as of last quarter is 113
Turnstone Biologics Corp. ( TSBX ) Debt/Capital as of last quarter is 3%
Other Balance Sheet Stats:
Turnstone Biologics Corp. ( TSBX ) has 38 million in cash on hand as of last quarter
Turnstone Biologics Corp. ( TSBX ) has 13 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Turnstone Biologics Corp. ( TSBX ) has 17 common shares outstanding as of last quarter
Turnstone Biologics Corp. ( TSBX ) has 0 million USD of preferred stock value
Academic Scores:
Turnstone Biologics Corp. ( TSBX ) Altman Z-Score is -0.13 as of last quarter
Turnstone Biologics Corp. ( TSBX ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
Turnstone Biologics Corp. ( TSBX ) largest shareholder is owning shares at 0.00 ($MM) value
Versant Ventures V, Llc(an insider) Bought 225000 shares of Turnstone Biologics Corp. ( TSBX ) for the amount of $2700000.00 on 2023-07-25
8.79% of Turnstone Biologics Corp. ( TSBX ) is held by insiders, and 34.17% is held by institutions
Turnstone Biologics Corp. ( TSBX ) went public on 2023-07-21
Other Turnstone Biologics Corp. ( TSBX ) financial metrics:
FCF:-71.80
Unlevered Free Cash Flow:0.00
EPS:-3.98
Operating Margin:-113.19
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-60.82
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Turnstone Biologics Corp. ( TSBX ) :
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.